Botensilimab/Balstilimab Breakthrough Data Presented at ASCO-GI Shows Unprecedented Tumor Shrinkage and Robust Biomarker Response in Prevalent Colorectal Cancer Population
Stock Information for Agenus Inc.
Loading
Please wait while we load your information from QuoteMedia.